Loading...
Loading...
CTMX| Name | Value |
|---|---|
| Revenues | 25.1M |
| Cost of Revenue | 0.5M |
| Gross Profit | 24.7M |
| Operating Expense | 33.1M |
| Operating I/L | -8.5M |
| Other Income/Expense | 2.0M |
| Interest Income | 2.0M |
| Pretax | -6.5M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -6.5M |
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company that develops antibody therapeutics using its Probody technology platform for cancer treatment. The company's product candidates include antibody drug conjugates (ADC) targeting CD166 and squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, it is developing Probody therapeutics in collaboration with industry leaders such as AbbVie, Amgen, Bristol-Myers Squibb, ImmunoGen, Pfizer, and Astellas Pharma. These partnerships drive the company's revenue through licensing agreements, milestone payments, and royalties.
